Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday. Several other research firms have also commented on MNPR. Chardan Capital restated a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in [...]